Last reviewed · How we verify

Wheezing — Treatment Landscape & Competitive Intelligence

Wheezing (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Wheezing, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Epipen epinephrine Pfizer Inc. alpha-Adrenergic Agonist [EPC] Alpha-1D adrenergic receptor 1948-01-01
Epinephrin Epinephrin United States Naval Medical Center, San Diego Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 2 drugs in Wheezing
  2. United States Naval Medical Center, San Diego · 1 drug in Wheezing

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Wheezing:

Cite this brief

Drug Landscape (2026). Wheezing — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/wheezing. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing